Literature DB >> 25687490

Anti-apoptosis effects on hearts of SHSST cyclodextrin complex in a carbon tetrachloride-induced cirrhotic cardiomyopathy rat model.

Cheng-Hsun Yang1, Wei-Jen Ting2, Pei-Ying Pai3, Sheng-Huang Chang4, Tsung-Jung Ho5, Jing-Ying Lin6, Fuu-Jen Tsai7, Viswanadha Vijaya Padama8, Yuhsin Tsai1, Chih-Yang Huang9.   

Abstract

Cirrhotic cardiomyopathy (CCM) is a common cardiac dysfunction in patients waiting for orthotopic liver transplantation (OLT). Carbon tetrachloride (CCl₄) intraperitoneal (IP) injection has been reported as successful in a cirrhosis-induced CCM model. In this work, we used the same assay for CCM induction using CCl₄ (0.2 mg/kg) IP injection twice per day for 14 days during the cardiac protection drugs treatment process. The cardiac protection drugs were silymarin (100 mg/kg/day), baicalein (30 mg/kg/day), San Huang Shel Shin Tang (SHSST, 30 mg/kg/day) and β-cyclodextrin modified SHSST (SHSSTc, 30 mg/kg/day and 300 mg/kg/day). After 4 weeks of treatment, the SHSSTc cardiac protection effects were determined through activation of the IGF1R cell survival pathway and inhibition of Fas-FADD death domain induced-apoptosis. SHSSTc cardiac protection was enhanced through β-cyclodextrin modification, which increased bio-availability, and displayed stronger protective effects than silymarin and baicalein, both of which are well-known liver protection drugs. Thus, SHSSTc might provide the best therapeutic benefit in CCM treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25687490     DOI: 10.4077/CJP.2015.BAD286

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  1 in total

1.  Silymarin Administration Attenuates Cirrhotic-induced Cardiac Abnormality in the Rats: A Possible Role of β1-adrenergic Receptors and L-type Voltage-Dependent Calcium Channels.

Authors:  Gholamreza Bayat; Roham Mazloom; Seyed Ali Hashemi; Khalil Pourkhalili; Parviz Fallah; Alireza Shams; Parvaneh Esmaeili; Azadeh Khalili
Journal:  Iran J Med Sci       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.